Abbvie Inc.

Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Other

Abbyie Inc.

Neil Wishart

Michael M Friedman

David J Calderwood

Kristine E Frank

Biqin C Li

Dawn M George

Lu Wang

Anna M Ericsson

Lee Daniel Arnold

Gavin C Hirst

Kent D Stewart

Maria A Argiriadi

Grier A Wallace

Kurt Ritter

Kevin R Woller

Paul Rafferty

Nathan Josephsohn

Eric R Goedken

Marlon D Cowart

Chen Zhao

Robert J Altenbach

Lawrence A Black

Michael Michaelides

Irene I Drizin

Huaqing Liu

Richard W Dixon

Michael L Curtin

Zhiqin Ji

Michael Morytko

Jeffrey W Voss

Kelly Mullen

Brian D Wakefield

Andrew Burchat

Jorge D Brioni

Robert J Gregg

Xiaoyun Wu

Gin C Hsieh

Timothy A Esbenshade

Marie P Honore

Bryan A Fiamengo

Arthur A Hancock

David J Babinski

Michael J Morytko

Nathan S Josephsohn

Michael L Friedman

Thomas D Gordon

Steven K Davidsen

Adrian Hobson

Yan Guo

Robin R Frey

Michael Z Hoemann

Yujia Dai

David Wayne Borhani

Eric C Breinlinger

Kevin Patrick Cusack

Robert V Talanian

Gagandeep K Somal

Claude E Barberis

Kathryn J Hancock, Legal Representative

Xiaolei Zhang

Lily K Abbott

Lu X Wang

David W Borhani

Kelly D Mullen

Biqin Li

The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Tricyclic compounds

The invention provide a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomer and isomer thereof wherein the variable are defined herein. The compound of the invention are useful for treating immunological and oncological conditions.

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

The invention provides a compound of Formula (Ie), 

Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof

The present invention is directed to novel aminopyrrolidines of formula I pharmaceutically acceptable salts thereof, metabolites thereof, isomers thereof, stereoisomers thereof or pro-drugs thereof, wherein the variables are as defined herein. The compounds of formula (I) are useful as chemokine receptor antagonists and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, cancers.

Aminopyrrolidines as chemokine receptor antagonists

Macrocyclic benzofused pyrimidine compounds, compositions comprising such compounds, methods for making the compounds, and methods of treating and preventing the progression of diseases, conditions and disorders using such compounds and compositions are described herein.

Macrocyclic benzofused pyrimidine derivatives

The present disclosure is directed to novel compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are as defined herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases and proliferative disorders and conditions, for example, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Crohn's disease, psoriasis and asthma.

[object Object]

Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

Indazole compounds

This invention discloses a method of treating pain by administering histamine Hreceptor ligands and compositions comprising the same.

Method for pain treatment

The present application is directed to compounds of the formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.

Substituted 4-amino isoxazolo[5,4-d]pyrimidines as kinase inhibitors

Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Thiopyrimidine and isothiazolopyrimidine kinase inhibitors

The present invention provides compounds of Formula I, including pharmaceutically acceptable salts and/or prodrugs thereof, where G, R, R, and Rare defined as described herein.

Pyrazolopyrimidines as therapeutic agents

The present invention is directed to pyrazolopyrimidine derivatives of formula (I)wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.

The present invention is directed to pyrazolopyrimidine derivatives which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.

Growing community of inventors

Jefferson, MA, United States of America

Neil Wishart